✦ LIBER ✦

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

✍ Scribed by Stephen Y. Chan; Alan N. Gordon; Robert E. Coleman; James B. Hall; Mark S. Berger; Matthew L. Sherman; Catharine B. Eten; Neil J. Finkler

Book ID: 105966601
Publisher: Springer-Verlag
Year: 2003
Tongue: English
Weight: 183 KB
Volume: 52
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-002-0343-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topotecan and carboplatin in patients wi

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

✍ Dominique Koensgen; Dirk Stengel; Antje Belau; Peter Klare; Guelten Oskay-Oezcel 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 324 KB

512 POSTER Interim results from a Phase

512 POSTER Interim results from a Phase 1/2 study of volociximab in combination with liposomal doxorubicin in patients with advanced epithelial ovarian or primary peritoneal carcinoma that relapsed after platinum/taxane chemotherapy

✍ P. Antonella; C. Sessa; A. Delmonte; G. Del Conte; A. Fasolo; E. Dall'O'; F. Zan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 76 KB

A multicenter, randomized, phase 2 clini

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer

✍ Angeles Alvarez Secord; Andrew Berchuck; Robert V. Higgins; Lawrence R. Nycum; M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

Impact of beta blocker medication in pat

Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer—a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG

✍ Heitz, Florian; du Bois, Andreas; Harter, Philipp; Lubbe, Dirk; Kurzeder, Christ 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 265 KB

606 Impact of Beta-blocker Medication in

606 Impact of Beta-blocker Medication in Patients with Platinum Sensitive Recurrent Ovarian Cancer – a Combined Analysis of 2 Prospective Multicenter Trials by the AGO Study Group, NCIC-CTG and EORTC-CTG

✍ Heitz, F.; du Bois, A.; Harter, P.; Kurzeder, C.; Lubbe, D.; Vergote, I.; Plante 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 80 KB